News Celgene MS pill can't beat older rival on disability progres... Phase 3 trial meets main efficacy endpoint, but disability progression stats cause concern.
News Novartis cues up Cosentyx as disease-modifying treatment for... Pharma begins early intervention trial after Cosentyx shows "disease modifying" properties
GlaxoSmithKline GSK's new CEO Walmsley paid 25% less than predecessor Witty GlaxoSmithKline (GSK) has confirmed rumours that its incoming CEO Emma Walmsley will be paid less than her predecessor, Sir Andrew Witty.
News Next gen psoriasis drugs show superiority to Stelara Guselkumab can also be used if older drug Stellara fails.
News Celgene files AML pill after fast-track trial The FDA has accepted Celgene’s filing for enasidenib.
Views & Analysis Orphan drugs will fuel pharma's future - and a pricing pushb... Evaluate predicts sales could approach $8bn if approved.
News Neurogene drops high-dose arm in Rett study after death The patient affected by a serious adverse event in Neurogene's clinical trial of Rett syndrome gene therapy has now died
Sales & Marketing Coming soon: The Life Sciences Industry Report 2025 – insigh... Prepare for 2025 with pharmaphorum’s Life Sciences Report, featuring expert insights on AI in drug development, gene therapy, and top industry trends
